Functional Roles of Optineurin in RGC-5 Cells
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2008 - March 31, 2010
Grant ID
G2008024
Goals
This study examines how proteins are transported inside cells and how neurites grow. The study may enhance understanding of mechanisms leading to neuronal cell loss in glaucoma and facilitate development of new treatments for glaucoma.
Summary
The researchers will study the roles of optineurin, a glaucoma gene, in two cellular functions in neuronal cells. One functions relates to the transportation of proteins inside cells, and the other governs whether and how neurites extend or grow in the cells. This study will provide new information about the role of optineurin in these important functions. It should also help explain why and how abnormal levels or mutations of optineurin may lead to glaucoma.
Related Grants
National Glaucoma Research
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
National Glaucoma Research
Using AI to Detect Loss of Connections Between Neural Cells in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Luca Della Santina, PhD, PharmD
Current Organization
University of Houston
Using AI to Detect Loss of Connections Between Neural Cells in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Luca Della Santina, PhD, PharmD
Current Organization
University of Houston
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet